Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy

作者全名："Que, Dan; Zou, Hongbo; Mao, Bijing; Zhang, Huan; Liang, Wei; Liu, Qin; Ke, Leiyu; Guo, Lijie; Xie, Qichao"

作者地址："[Que, Dan; Zou, Hongbo; Mao, Bijing; Zhang, Huan; Liang, Wei; Liu, Qin; Xie, Qichao] Chongqing Med Univ, Affiliated Hosp 3, Dept Oncol, Chongqing, Peoples R China; [Ke, Leiyu; Guo, Lijie] Shanghai OrigiMed Co Ltd, Med Dept, Shanghai, Peoples R China"

通信作者："Xie, QC (通讯作者)，Chongqing Med Univ, Affiliated Hosp 3, Dept Oncol, Chongqing, Peoples R China."

来源：FRONTIERS IN ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000897836300001

JCR分区：Q2

影响因子：4.7

年份：2022

卷号：12

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：multiple lines of therapy; lung adenocarcinoma; pathological complete remission; targeted therapy; ALK plus

摘要："IntroductionTraditional therapeutic approaches for the treatment of advanced non-small-cell lung cancer (NSCLC) are based on chemotherapy. However, the discovery and understanding of oncogenic driver alterations has led to the development of targeted therapies that have substantially improved patient outcomes. Still, to date, there have been no reports of patients with advanced anaplastic lymphoma kinase (ALK)-positive lung cancer achieving clinical complete response (cCR) in the systemic lesion and pathological complete remission (pCR) in primary lung lesion after multiple lines of conversion therapy. MethodsIn this case, a 55-year-old man was diagnosed with ALK-positive, stage IV lung adenocarcinoma using immunohistochemistry and next generation sequencing (NGS) tests. ResultsCrizotinib and two other ATP-competitive ALK inhibitors, ceritinib and alectinib, were used respectively as first-line, second-line, and third-line therapy. The patient received treatment with crizotinib and achieved partial response (PR), but 5 months later the efficacy was evaluated as progressive disease (PD). Ceritinib was used as the second-line treatment, but the disease progressed 6 months later. Alectinib was used as the third-line treatment, but the efficacy was evaluated as PD. From April 2019 to November 2019, the patient received 4 cycles of induction chemotherapy with pemetrexed/carboplatin/bevacizumab and then switched to pemetrexed/bevacizumab as the fourth-line treatment, and received the fifth line treatment, cetuximab/paclitaxel liposome/nedaplatin, for 1 cycle, but the disease still progressed. Then the patient received the sixth line of treatment, camrelizumab/lorlatinib, for 9 antitumor cycles, resulting in PR. The patient underwent surgery followed by maintenance treatment with lorlatinib and achieved cCR. To our knowledge, this is the first documented case of cCR in a patient with ALK-positive advanced lung adenocarcinoma treated with multiple lines of therapy followed by surgical treatment. DiscussionThis case reveals the possible survival benefit of immunotherapy after multiple line treatment in ALK-positive advanced lung adenocarcinoma, indicating that it is possible find new therapeutic targets based on NGS molecular detection and provide precise therapeutic strategies for clinical practice when drug resistance or progression occurs in cancer therapy."

基金机构：　

基金资助正文：